文献速递肿瘤 PET/CT

18F-FDG PET/CT预测乳腺癌治疗反应

18F-FDG PET/CT for prediction of response in breast cancer.
PubMed 文献 · Semin Nucl Med · 2026-01-09

乳腺癌异质性强,早期准确评估治疗反应对个体化治疗至关重要。18F-FDG PET/CT可无创测量肿瘤代谢、异质性及早期治疗适应,基线SUVmax、MTV、TLG反映侵袭性,早期变化(ΔSUV、ΔMTV/TLG)预测病理完全缓解(pCR)具高阴性预测值。PET衍生列线图整合临床、分子和代谢数据优于单纯临床病理模型,影像组学和人工智能进一步细化预测。

要点

  • 基线SUVmax、MTV、TLG反映肿瘤增殖驱动力和侵袭性。
  • 1-2周期后ΔSUV、ΔMTV/TLG预测pCR具高阴性预测值。
  • PET衍生列线图整合临床、分子、代谢数据优于临床病理模型。

核心结论

  • 18F-FDG PET/CT已从分期工具转变为精准反应预测工具,尤其在HER2阳性和三阴性乳腺癌中。

主要发现

  • 基线SUVmax、MTV、TLG反映增殖驱动力和侵袭性。
  • 早期变化(ΔSUV、ΔMTV/TLG,1-2周期后)预测pCR具高阴性预测值。
  • PET衍生列线图整合临床、分子和代谢数据,优于单纯临床病理模型。
  • 影像组学和人工智能分析通过量化空间异质性和亚型特异性建模进一步优化预测。

关键数值与推荐

  • EANM/SNMMI指南和NCCN推荐越来越多地支持18F-FDG PET/CT用于高危或局部晚期乳腺癌的分期和反应监测。

临床怎么用

  • 整合AI驱动列线图支持适应性、个体化决策,在最大化获益的同时减少毒性和费用。

局限性

  • 需前瞻性多中心验证并与EANM/SNMMI/NCCN指南一致,以巩固PET在适应性肿瘤学中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer remains one of the most heterogeneous malignancies, with marked variability in biology, therapeutic sensitivity, and clinical outcomes. As treatment strategies evolve toward individualized approaches, early and accurate assessment of response has become critical for optimizing outcomes and minimizing toxicity. Recent Findings: ¹⁸F-FDG PET/CT provides a biologically grounded, non-invasive measure of tumour metabolism, heterogeneity, and early treatment adaptation. Baseline metrics such as SUVmax, metabolic tumour volume (MTV), and total lesion glycolysis (TLG)-reflect proliferative drive and aggressiveness, while early changes (ΔSUV, ΔMTV/TLG after 1-2 cycles) predict pathological complete response (pCR) with high negative predictive value. PET-derived nomograms integrating clinical, molecular, and metabolic data outperform clinicopathologic models alone. Radiomic and artificial-intelligence (AI) analyses further refine prediction by quantifying spatial heterogeneity and enabling subtype-specific modelling. Joint EANM/SNMMI guidelines and NCCN recommendations increasingly endorse ¹⁸F-FDG PET/CT for staging and response monitoring in high-risk or locally advanced disease. ¹⁸F-FDG PET/CT has transitioned from staging to precision-response prediction, particularly in HER2-positive and triple-negative breast cancer. Integration into AI driven nomograms supports adaptive, patient-tailored decisions that minimize toxicity and cost while maximizing benefit. Prospective multicentre validation aligned with EANM/SNMMI/NCCN guidance will consolidate PET's role in adaptive oncology.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Vorster M, Sathekge M. 18F-FDG PET/CT for prediction of response in breast cancer. Semin Nucl Med. 2026. PMID: 41513559. doi:10.1053/j.semnuclmed.2025.11.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。